Abstract
Although antiretroviral therapy can suppress HIV-1 infection to undetectable levels of plasma viremia, integrated latent HIV-1 genomes that encode replication-competent virus persist in resting CD4+ T cells. This latent HIV-1 reservoir represents a major barrier to a cure. Currently, there are substantial efforts to identify therapeutic approaches that will eliminate or reduce the size of this latent HIV-1 reservoir. In this regard, a sensitive assay that can accurately and rapidly quantify inducible, replication-competent latent HIV-1 from resting CD4+ T cells is essential for HIV-1 eradication studies. Here we describe a reporter cell-based assay to quantify inducible, replication-competent latent HIV-1. This assay has several advantages over existing technology in that it (i) is sensitive; (ii) requires only a small blood volume; (iii) is faster, less labor intensive, and less expensive; and (iv) can be readily adapted into a high-throughput format. Using this assay, we show that the size of the inducible latent HIV-1 reservoir in aviremic participants on therapy is approximately 70-fold larger than previous estimates.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Impact of misclassified defective proviruses on HIV reservoir measurements
Nature Communications Open Access 13 July 2023
-
TZM-gfp cells: a tractable fluorescent tool for analysis of rare and early HIV-1 infection
Scientific Reports Open Access 16 November 2020
-
Clearance of HIV infection by selective elimination of host cells capable of producing HIV
Nature Communications Open Access 13 August 2020
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout



Change history
21 June 2017
In the version of this article initially published online, the description of the fPVE calculation was incorrect. The correct description is as follows: “The fPVE was calculated by dividing IUPM values by the total HIV-1 DNA copies/million cells, as described by Cillo et al.18.” The error has been corrected in the print, PDF and HTML versions of this article.
References
Bailey, J.R. et al. Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J. Virol. 80, 6441–6457 (2006).
Finzi, D. et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 5, 512–517 (1999).
Siliciano, J.D. et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat. Med. 9, 727–728 (2003).
Lewin, S.R. et al. Use of real-time PCR and molecular beacons to detect virus replication in human immunodeficiency virus type 1-infected individuals on prolonged effective antiretroviral therapy. J. Virol. 73, 6099–6103 (1999).
Pasternak, A.O. et al. Cellular levels of HIV unspliced RNA from patients on combination antiretroviral therapy with undetectable plasma viremia predict the therapy outcome. PLoS One 4, e8490 (2009).
Strain, M.C. et al. Highly precise measurement of HIV DNA by droplet digital PCR. PLoS One 8, e55943 (2013).
Vandergeeten, C. et al. Cross-clade ultrasensitive PCR-based assays to measure HIV persistence in large-cohort studies. J. Virol. 88, 12385–12396 (2014).
Procopio, F.A. et al. A novel assay to measure the magnitude of the inducible viral reservoir in HIV-infected individuals. EBioMedicine 2, 874–883 (2015).
Ho, Y.C. et al. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 155, 540–551 (2013).
Bruner, K.M. et al. Defective proviruses rapidly accumulate during acute HIV-1 infection. Nat. Med. 22, 1043–1049 (2016).
Eriksson, S. et al. Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog. 9, e1003174 (2013).
Siliciano, J.D. & Siliciano, R.F. Enhanced culture assay for detection and quantitation of latently infected, resting CD4+ T-cells carrying replication-competent virus in HIV-1-infected individuals. Methods Mol. Biol. 304, 3–15 (2005).
Bruner, K.M., Hosmane, N.N. & Siliciano, R.F. Towards an HIV-1 cure: measuring the latent reservoir. Trends Microbiol. 23, 192–203 (2015).
Clouse, K.A. et al. Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T cell clone. J. Immunol. 142, 431–438 (1989).
Jordan, A., Bisgrove, D. & Verdin, E. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J. 22, 1868–1877 (2003).
Folks, T.M. et al. Biological and biochemical characterization of a cloned Leu-3- cell surviving infection with the acquired immune deficiency syndrome retrovirus. J. Exp. Med. 164, 280–290 (1986).
Goel, R. et al. Structure/function studies of HIV-1(1) reverse transcriptase: dimerization-defective mutant L289K. Biochemistry 32, 13012–13018 (1993).
Cillo, A.R. et al. Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy. Proc. Natl. Acad. Sci. USA 111, 7078–7083 (2014).
Ananworanich, J. & Mellors, J.W. How much HIV is alive? The challenge of measuring replication competent HIV for HIV cure research. EBioMedicine 2, 788–789 (2015).
Gandhi, R.T. et al. No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 59, 229–235 (2012).
Malnati, M.S. et al. A universal real-time PCR assay for the quantification of group-M HIV-1 proviral load. Nat. Protoc. 3, 1240–1248 (2008).
Cillo, A.R. et al. Plasma viremia and cellular HIV-1 DNA persist despite autologous hematopoietic stem cell transplantation for HIV-related lymphoma. J. Acquir. Immune Defic. Syndr. 63, 438–441 (2013).
Chargin, A. et al. Identification and characterization of HIV-1 latent viral reservoirs in peripheral blood. J. Clin. Microbiol. 53, 60–66 (2015).
Biswas, N. et al. ADAR1 is a novel multi targeted anti-HIV-1 cellular protein. Virology 422, 265–277 (2012).
Rosenbloom, D.I. et al. Designing and interpreting limiting dilution assays: general principles and applications to the latent reservoir for human immunodeficiency virus-1. Open Forum Infect. Dis. 2, ofv123 (2015).
Acknowledgements
We thank L. Caruso and A. Anthony (University of Pittsburgh, Pittsburgh) for their technical assistance; J. Mellors (University of Pittsburgh, Pittsburgh) for plasma viral-load measurements and for discussion during the development of the assay; P. Tarwater (University of Texas, El Paso) and C. Shen (University of Pittsburgh, Pittsburgh) for statistical consultation; W. Buchanan (University of Pittsburgh, Pittsburgh) for recruitment of the Multicenter AIDS Cohort Study participants for the study; and participants of the Pittsburgh portion of the MACS for donating blood for this study. This work was supported by NIH grants U01-AI35041 (C.R.R.), R21-AI119117 (N.S.C.) and NIH Fogarty training grant fellowship D43TW010039 (P.G.).
Author information
Authors and Affiliations
Contributions
P.G., A.S., N.S.-C., R.B.M., B.K.P., C.R.R., N.J.V., and Y.C. designed the study, analyzed data, and wrote the manuscript. D.R., M.D., A.S., A.C., J.M.Z., and N.S.G. performed the experiments.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Text and Figures
Supplementary Tables 1–3 and Supplementary Figures 1–2. (PDF 351 kb)
Rights and permissions
About this article
Cite this article
Sanyal, A., Mailliard, R., Rinaldo, C. et al. Novel assay reveals a large, inducible, replication-competent HIV-1 reservoir in resting CD4+ T cells. Nat Med 23, 885–889 (2017). https://doi.org/10.1038/nm.4347
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.4347
This article is cited by
-
Impact of misclassified defective proviruses on HIV reservoir measurements
Nature Communications (2023)
-
HIV Reservoir: How to Measure It?
Current HIV/AIDS Reports (2023)
-
TZM-gfp cells: a tractable fluorescent tool for analysis of rare and early HIV-1 infection
Scientific Reports (2020)
-
Clearance of HIV infection by selective elimination of host cells capable of producing HIV
Nature Communications (2020)
-
Single-dose bNAb cocktail or abbreviated ART post-exposure regimens achieve tight SHIV control without adaptive immunity
Nature Communications (2020)